Fig. 2

The details in antivirals. a The use of antivirals was evaluated according to severity. A total of 66 facilities responded the survey (65 facilities for mild and 66 facilities for moderate I or more severe). “ + ” indicates administration of the antivirals, and “-” indicates no administration of the antivirals. Among those with mild disease, 27.7% of facilities (18 facilities) administered antivirals, and 72.3% (47 facilities) did not. In patients with moderate disease I or more severe conditions, 66.7% (44 facilities) administered antivirals, and 33.3% (22 facilities) were not. b The numbers of facilities treated with either remdesivir or favipiravir at each severity were evaluated. Among 18 facilities administering antivirals in mild disease, 3 facilities (16.7%) administered remdesivir, 7 facilities (38.9%) administered favipiravir and other 8 facilities (44.4%) did not answer the question or administered anti-SARS-CoV-2 monoclonal antibodies. Among 44 facilities administering antivirals in moderate disease I or more severe disease, 29 facilities (65.9%) administered remdesivir, 7 facilities (15.9%) administered favipiravir and other 8 facilities (18.2%) did not answer the question or administered anti-SARS-CoV-2 monoclonal antibodies